- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.09. | Stifel cuts BridgeBio Oncology price target on pipeline shift | 1 | Investing.com | ||
| 08.09. | BridgeBio Oncology Therapeutics, Inc. - 8-K, Current Report | 14 | SEC Filings | ||
| 08.09. | BridgeBio Oncology Therapeutics, Inc.: BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers | 180 | GlobeNewswire (Europe) | BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRASG12C inhibitor-experienced NSCLC patientsBBO-8520 monotherapy continues to show highly competitive... ► Artikel lesen | |
| 11.08. | BridgeBio Oncology Therapeutics, Inc.: BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 11.08. | BridgeBio Oncology Therapeutics, Inc.: BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress | 482 | GlobeNewswire (Europe) | Continued to advance monotherapy and combination cohorts for all clinical programsInitiated dosing of BBO-11818 in combination with cetuximab and after the end of the quarter, initiated dosing of... ► Artikel lesen | |
| 11.08. | BridgeBio Oncology Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.07. | JPMorgan startet Coverage für BridgeBio Oncology mit "Overweight"-Rating | 2 | Investing.com Deutsch | ||
| BRIDGEBIO ONCOLOGY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 08.07. | JPMorgan initiates BridgeBio Oncology stock with overweight rating | 2 | Investing.com | ||
| 22.06. | BridgeBio Oncology Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.06. | Oppenheimer initiates BridgeBio Oncology stock rating at Outperform | 1 | Investing.com | ||
| 12.05. | BridgeBio Oncology Therapeutics, Inc. GAAP EPS of -$526.11 | 2 | Seeking Alpha | ||
| 12.05. | BridgeBio Oncology Therapeutics, Inc.: BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress | 487 | GlobeNewswire (Europe) | Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programsAnnounced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-11818... ► Artikel lesen | |
| 12.05. | BridgeBio Oncology Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.05. | BridgeBio Oncology Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 12.05. | BridgeBio Oncology Therapeutics, Inc.: BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 29.04. | BridgeBio Oncology Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.04. | BridgeBio Oncology presents preclinical data on KRAS inhibitor | 10 | Investing.com | ||
| 22.04. | BridgeBio Oncology Therapeutics, Inc.: BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026 | 2 | GlobeNewswire (USA) | ||
| 22.04. | BridgeBio Oncology Therapeutics appoints new CEO and COO | 3 | Seeking Alpha | ||
| 22.04. | BridgeBio Oncology names Pedro Beltran as new CEO | 1 | Investing.com |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HEMAB THERAPEUTICS | 41,190 | 0,00 % | Gubra A/S: Gubra collaboration partner Hemab announces first participant dosed in Phase 1 clinical trial of HMB-003, an investigational therapy for the management of heavy menstrual bleeding | Today, Gubra announced that its partner Hemab Therapeutics has dosed the first healthy volunteer in its Phase 1 clinical trial evaluating HMB-003, an investigational therapy for the management of heavy... ► Artikel lesen | |
| SCRIBE THERAPEUTICS | 33,000 | 0,00 % | Biotech Stocks At 52-Week Highs - Scribe Therapeutics Continues Rise After Nasdaq Debut, Royalty Pharma, Haemonetics, 10x Genomics, Labcorp Holdings | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 20, 2026, driven by key catalysts such as new product launches and the prospective release of data from clinical... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 45,320 | 0,00 % | Biotech Options Buzz: UTHR, NMRA, EWTX | ||
| DYNE THERAPEUTICS | 17,110 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| SHATTUCK LABS | 6,010 | 0,00 % | Shattuck Labs, Inc.: Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights | - Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A binding, potentially enabling... ► Artikel lesen | |
| ABSCI | 9,650 | 0,00 % | Absci auf Morgan Stanley Healthcare-Konferenz: KI-Plattform im klinischen Test | ||
| MBX BIOSCIENCES | 62,91 | 0,00 % | MBX Biosciences, Inc.: MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism | Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail results and durable one-year clinical benefit Global registrational trial to enroll approximately 160 adults with HP to support... ► Artikel lesen | |
| TYRA BIOSCIENCES | 25,730 | 0,00 % | Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported? | ||
| QIAGEN | 38,410 | -0,51 % | AKTIE IM FOKUS: Qiagen ziehen an - Magazinbericht schürt Übernahmefantasie | FRANKFURT (dpa-AFX) - Bei den Aktien von Qiagen hat am Donnerstag ein Magazinbericht die bereits bestehende Übernahmefantasie angeheizt. Die Aktien des Molekulardiagnostik-Unternehmens zogen am Mittag... ► Artikel lesen | |
| ELECTRA THERAPEUTICS | 13,500 | +1,89 % | Electra Therapeutics, Inc.: Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public Offering | SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines... ► Artikel lesen | |
| CABALETTA BIO | 2,550 | 0,00 % | Cabaletta Bio, Inc. - 8-K, Current Report | ||
| PRAXIS PRECISION MEDICINES | 299,28 | +0,11 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| CANDEL THERAPEUTICS | 10,850 | 0,00 % | Candel Therapeutics auf der H.C. Wainwright Konferenz: Fokus auf Prostatakrebs-Therapie | ||
| COGENT BIOSCIENCES | 31,480 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 117,80 | +0,04 % | Kymera Therapeutics auf Morgan Stanley Konferenz: Offensive bei oralen Degradern |
Das Unternehmen BRIDGEBIO ONCOLOGY THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 4,750 Euro und damit -0,42 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BRIDGEBIO ONCOLOGY THERAPEUTICS INC finden Sie auf Wallstreet Online.